Home > Healthcare > Drug Device Combination > Therapeutic Systems > Amniotic Membrane Market

Amniotic Membrane Market Trends

Report ID: GMI8336
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Amniotic Membrane Market Trends

The market is experiencing significant growth, driven by its wide-ranging applications in healthcare, especially in wound care, ophthalmology, and regenerative medicine.

The adoption of amniotic membrane transplantation to address ocular surface disorders, including corneal ulcers, chemical burns, and conjunctival defects, is increasing in ophthalmic surgeries. The rising popularity of cryopreserved amniotic membranes for corneal repair and regeneration stems from their efficacy in promoting healing and minimizing scarring in corneal epithelial defects and other surface disorders.
There's growing demand for amniotic membrane products in treating chronic wounds such as diabetic foot ulcers and pressure ulcers and venous leg ulcers. Additionally, due to their healing-promoting properties and pain-reducing effects, amniotic membranes are increasingly used in burn care.
Recent advancements in cryopreservation techniques have not only enhanced the efficacy and shelf-life of amniotic membrane products but also ensured the retention of their biological properties, amplifying their medical effectiveness.
The introduction of dehydrated amniotic membrane products has further invigorated the market, given their extended shelf life, ease of storage and transport, and comparable therapeutic benefits to their cryopreserved counterparts.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The industry was valued at approximately USD 1.7 billion in 2023 and is estimated to grow at a 7.9% CAGR from 2024 to 2032, driven by its regenerative properties and applications in medical treatments and surgeries.

The cryopreserved segment is forecasted to reach USD 1.7 billion by 2032 due to its extensive use in various medical disciplines, such as ophthalmology, where it treats corneal defects, promotes faster healing, and reduces inflammation and scarring.

The U.S. market is projected to reach USD 1.1 billion by 2032, driven by well-established healthcare facilities, leading industry players, a focus on regenerative medicine, and the rapid adoption of advanced technologies.

Prominent participants include Amnio Technology, LLC, Applied Biologics LLC, BioTissue Holdings Inc., Celularity Inc., Corza Health, Inc., Integra LifeSciences Holdings Corporation, MiMedx Group, Inc., Organogenesis Holdings Inc., Skye Biologics, Inc., and Smith & Nephew plc.